Results 271 to 280 of about 2,535,602 (380)

A Bayesian quasi-probability approach to inferring the past of quantum observables

, 2014
Mankei Tsang
openalex   +2 more sources

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source

A comparative study of different parameter estimation methods for predictive models of Normal Tissue Complication Probability (NTCP) of radiation-induced temporal lobe injury following intensity-modulated radiotherapy in nasopharyngeal carcinoma. [PDF]

BMC Cancer
OuYang H, Liu Y, He X, Zhang J, Tao L, Liu M, Ding J, Hu R, Hu J, Huang Z, Deng S, Wu J, Xu Z, Luo Q, Zeng L.   +14 more
europepmc   +1 more source

Robust Bayesian Sensitivity Analysis for Case–Control Studies with Uncertain Exposure Misclassification Probabilities

, 2015
Timothy Shin Heng Mak, Nicky Best, Lesley Rushton   +2 more
openalex   +2 more sources

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

Clinical Pharmacology &Therapeutics, EarlyView.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj, Dmitry Shchelokov, Oleg Demin Jr, Homer C. Adams 3rd, Yan Feng, Leonid Gibiansky, Saskia van der Lee, Anandhi Johri, Merzu Belete, Alexander Muik, Porntula Panorchan, Özlem Türeci, Uğur Sahin, Tahamtan Ahmadi, Manish Gupta, Oleg Demin, Craig Thalhauser   +16 more
wiley   +1 more source

Bayesian methods as a complementary tool: balancing innovation and rigor in critical care research. [PDF]

Crit Care
Lu S, Liu K, Chen XY, Luo JC.
europepmc   +1 more source

SNP prioritization using a Bayesian probability of association. [PDF]

Genet Epidemiol, 2013
Thompson JR, Gögele M, Weichenberger CX, Modenese M, Attia J, Barrett JH, Boehnke M, De Grandi A, Domingues FS, Hicks AA, Marroni F, Pattaro C, Ruggeri F, Borsani G, Casari G, Parmigiani G, Pastore A, Pfeufer A, Schwienbacher C, Taliun D, CKDGen Consortium, Fox CS, Pramstaller PP, Minelli C.   +23 more
europepmc   +1 more source

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure‐Response Analyses

Clinical Pharmacology &Therapeutics, EarlyView.
Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow, Marek Wardecki, Michael Storek, Nancy Wong   +3 more
wiley   +1 more source

Confidence interval forecasting model of small watershed flood based on compound recurrent neural networks and Bayesian. [PDF]

PLoS One
Wang S, Xu O.
europepmc   +1 more source

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman, Marjon H. Cnossen, Ron A.A. Mathot, on behalf of the OPTI‐CLOT study group and SYMPHONY consortium, S. H. Reitsma   +4 more
wiley   +1 more source